These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

475 related articles for article (PubMed ID: 19788468)

  • 1. Elevated saliva calcitonin gene-related peptide levels during acute migraine predict therapeutic response to rizatriptan.
    Cady RK; Vause CV; Ho TW; Bigal ME; Durham PL
    Headache; 2009 Oct; 49(9):1258-66. PubMed ID: 19788468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Salivary levels of CGRP and VIP in rhinosinusitis and migraine patients.
    Bellamy JL; Cady RK; Durham PL
    Headache; 2006 Jan; 46(1):24-33. PubMed ID: 16412148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical-biochemical correlates of migraine attacks in rizatriptan responders and non-responders.
    Sarchielli P; Pini LA; Zanchin G; Alberti A; Maggioni F; Rossi C; Floridi A; Calabresi P
    Cephalalgia; 2006 Mar; 26(3):257-65. PubMed ID: 16472331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An exploratory study of salivary calcitonin gene-related peptide levels relative to acute interventions and preventative treatment with onabotulinumtoxinA in chronic migraine.
    Cady R; Turner I; Dexter K; Beach ME; Cady R; Durham P
    Headache; 2014 Feb; 54(2):269-77. PubMed ID: 24147647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Migraine treatment with rizatriptan and non-triptan usual care medications: a pharmacy-based study.
    Cady R; Martin V; Adelman J; Diamond M; Sajjan S; Hu XH
    Headache; 2004 Oct; 44(9):900-7. PubMed ID: 15447699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elimination of migraine-associated nausea in patients treated with rizatriptan orally disintegrating tablet (ODT): a randomized, double-blind, placebo-controlled study.
    Freitag F; Taylor FR; Hamid MA; Rodgers A; Hustad CM; Ramsey KE; Skobieranda F
    Headache; 2008 Mar; 48(3):368-77. PubMed ID: 18047500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rizatriptan 10-mg wafer versus usual nontriptan therapy for migraine: analysis of return to function and patient preference.
    Pascual J; García-Moncó C; Roig C; Yusta Izquierdo A; López-Gil A;
    Headache; 2005 Oct; 45(9):1140-50. PubMed ID: 16178944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early treatment of migraine with rizatriptan: a placebo-controlled study.
    Mathew NT; Kailasam J; Meadors L
    Headache; 2004; 44(7):669-73. PubMed ID: 15209688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term efficacy and tolerability of rizatriptan wafers in migraine.
    Cady R; Crawford G; Ahrens S; Hairwassers D; Getson A; Visser WH; Lines C;
    MedGenMed; 2001 Jun; 3(3):1. PubMed ID: 11549974
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Rizatriptan 10 mg administered early in a migraine attack.
    Cady R; Martin V; Mauskop A; Rodgers A; Hustad CM; Ramsey KE; Skobieranda F
    Headache; 2006 Jun; 46(6):914-24. PubMed ID: 16732837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rizatriptan vs. rizatriptan plus trimebutine for the acute treatment of migraine: a double-blind, randomized, cross-over, placebo-controlled study.
    Krymchantowski AV; Filho PF; Bigal ME
    Cephalalgia; 2006 Jul; 26(7):871-4. PubMed ID: 16776704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rizatriptan in the treatment of migraine.
    Dahlof CG; Rapoport AM; Sheftell FD; Lines CR
    Clin Ther; 1999 Nov; 21(11):1823-36; discussion 1821. PubMed ID: 10890255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid responders to frovatriptan in acute migraine treatment: results from a long-term, open-label study.
    Spierings EL; Keywood C
    Pain Med; 2009; 10(4):633-8. PubMed ID: 19453958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of recent prior opioid use on rizatriptan efficacy. A post hoc pooled analysis.
    Ho TW; Rodgers A; Bigal ME
    Headache; 2009 Mar; 49(3):395-403. PubMed ID: 19222588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time to pain freedom and onset of pain relief with rizatriptan 10 mg and prescription usual-care oral medications in the acute treatment of migraine headaches: a multicenter, prospective, open-label, two-attack, crossover study.
    Bell CF; Foley KA; Barlas S; Solomon G; Hu XH
    Clin Ther; 2006 Jun; 28(6):872-80. PubMed ID: 16860170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rizatriptan 5 mg for the acute treatment of migraine in adolescents: results from a double-blind, single-attack study and two open-label, multiple-attack studies.
    Visser WH; Winner P; Strohmaier K; Klipfel M; Peng Y; McCarroll K; Cady R; Lewis D; Nett R;
    Headache; 2004 Oct; 44(9):891-9. PubMed ID: 15447698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preference for rizatriptan 10-mg wafer vs. eletriptan 40-mg tablet for acute treatment of migraine.
    Láinez MJ; Evers S; Kinge E; Allais G; Allen C; Rao NA; Massaad R; Lis K
    Cephalalgia; 2006 Mar; 26(3):246-56. PubMed ID: 16472330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Times to pain relief and pain freedom with rizatriptan 10 mg and other oral triptans.
    Ng-Mak DS; Hu XH; Chen Y; Ma L; Solomon G
    Int J Clin Pract; 2007 Jul; 61(7):1091-111. PubMed ID: 17537184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects on productivity and quality of life of rizatriptan for acute migraine: a workplace study.
    Láinez MJ; López A; Pascual AM
    Headache; 2005; 45(7):883-90. PubMed ID: 15985105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eletriptan in migraine patients reporting unsatisfactory response to rizatriptan.
    Goldstein J; Tiseo PT; Albert KS; Li C; Sikes CR
    Headache; 2006; 46(7):1142-50. PubMed ID: 16866718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.